MAP2K7 and neoplasm: The results suggested that high PLEKHA4 expression could increase the drug IC50s and decrease the drug sensitivities of B-Raf inhibitors, including PLX-4720, Vemurafenib, PLX-8394, SB-590885, Encorafenib, Dabrafenib, TAK-632 and MLN-2480, as well as the ERK and MEK inhibitors HYPOTHEMYCIN, GDC-0994 and CC-90003, indicating that PLEKHA4 expression might be related to the drug resistance of tumor cells.